Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 08 October 2012
A host of biopharmaceutical regulatory issues are said to be at the forefront of trade talks between the US and a group of 11 countries in the Asia-Pacific, potentially complicating both the agreement and the Obama administration's already complicated relationship with the pharmaceutical industry, reports Reuters.
The agreement in question is known as the Transpacific Partnership (TPP)-a regional trade policy long under negotiation and periodically subject to transparency concerns from legislators and public advocacy groups who fear the US Trade Representative (USTR) is keeping negotiations secret to limit public input. Those concerns apparently led to House Oversight Committee Chairman Darrell Issa (R-CA) leaking part of the proposed agreement.
But even if transparency concerns remain, it is the Obama administration's stance on data exclusivity for biological medicines that has earned the ire of the biopharmaceutical industry, reports Reuters.
"The White House, for whatever reason, is pursuing a trade policy that (potentially is at odds with) US law," said Harrison Cook, a vice president at pharmaceutical manufacturer Eli Lilly, to Reuters. "It is difficult to understand, given the strong support and the realization this that kind of protection is needed for the future of the industry."
Under the terms of Title XIII of the Patient Protection and Affordable Care Act (PPACA), sometimes referred to as "Obamacare," manufacturers of biological medicines were granted 12 years of data protection for their biological products, during which time manufacturers of generic biological products-also known as biosimilars or follow-on biologics-could not obtain approval from the US Food and Drug Administration (FDA).
According to one congressional staffer involved in the negotiations, the 12 years of exclusivity was a serendipitous turn for biopharmaceutical companies, who had sought the comparatively long period of exclusivity from the outset. Congressional Democrats, some of whom sought exclusivity periods as short as five years, were ultimately defeated after some Democrats with biotechnology industries headquartered in their districts broke ranks to side with Republicans in support of lengthy exclusivity provisions.
The Obama administration's trade agreement so far isn't pushing explicitly for those 12 years of exclusivity, leaving open the potential for USTR negotiators to settle on a lesser number of years such as the seven years of exclusivity originally sought by both the Obama administration and congressional Democrats during the 2010 debate over the PPACA.
At issue for biopharmaceutical companies is the amount of time and money it takes to generate data showing their product is both safe and effective. After the protected period of data exclusivity ends, generic companies are allowed to reference the data as a means to show that their highly similar product will-presumably-exhibit the same safety and efficacy profile as the originator. Given the high cost of developing the data, branded biologics companies want more time to recoup their up-front costs before being subject to generic competition which historically has eroded much of the product's market share.
Though negotiations continue, the USTR said it is attempting to address underlying issues related to data exclusivity "before proposing any specific provisions."
Tags: Trade Agreement, TPP, Data Exclusivity, Obama Administration, White House, Obamacare, Latest News, PPACA, Biosimilars, Biologics
Regulatory Focus newsletters
All the biggest regulatory news and happenings.